Apyx Medical (APYX) Projected to Announce Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $13.29 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. On average, analysts expect Apyx Medical to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Apyx Medical Stock Performance

Apyx Medical stock opened at $2.60 on Tuesday. The company has a market cap of $109.52 million, a PE ratio of -13.00 and a beta of 1.45. The company has a fifty day moving average price of $2.76 and a two-hundred day moving average price of $3.60. The company has a debt-to-equity ratio of 3.19, a current ratio of 5.68 and a quick ratio of 4.53. Apyx Medical has a 12 month low of $2.25 and a 12 month high of $5.08.

Analysts Set New Price Targets

A number of brokerages have weighed in on APYX. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. Maxim Group initiated coverage on shares of Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price target for the company. HC Wainwright initiated coverage on shares of Apyx Medical in a report on Monday, July 13th. They issued a “buy” rating and a $7.00 price target for the company. Finally, Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Apyx Medical has an average rating of “Moderate Buy” and a consensus price target of $6.50.

About Apyx Medical

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.